PsychPGx Lab Projects
The widespread use of the atypical antipsychotic, clozapine, has been limited due to considerable risks of rare but potentially fatal adverse side effects. Among these adverse effects, cardiac side effects such as myocarditis are under-appreciated despite their association with increased risk of death. Unfortunately, our ability to identify those at greatest risk for clozapine-associated cardiac side effects is poor.
In response to this gap in knowledge, we are conducting the Pharmacogenetics of Clozapine-Induced Myocarditis (PROCLAIM) study. The PROCLAIM study will unite investigators around the world to uncover genomic markers that could be used preemptively by clinicians to identify those patients at highest risk for myocarditis from clozapine therapy and identify the mechanism by which clozapine induces myocardial inflammation and damage.
We invite all clinicians and/or investigators who have cared for and/or studied individuals that have developed myocarditis following clozapine exposure to join the PROCLAIM Study. We are particularly interested in members who can contribute samples and/or genomic data that would enable pooled analyses to be performed. Please contact us if you are interested in becoming a site.
The Pharmacogenetics Resource for Enhanced Education and Monitoring of Pharmacological Therapy (PREEMPT) Project is in the planning stages. In collaboration with Dr Mark Yarema, Director of the Poison and Drug Information Service the PREEMPT Project is being designed to provide easy accesses to state-of-the-art pharmacogenetics testing and education for clinicians and patients in Alberta.
We are one of several sites participating in the Genomics of Electroconvulsive Therapy (ECT) International Consortium (GenECT-IC). One of the main aims of GenECT-IC is to study the genomics of ECT response and side effects in an international cohort of patients with unipolar / bipolar depression.